REVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok

Size: px
Start display at page:

Download "REVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok"

Transcription

1 Personalized medicine in lung cancer: what we need to know Tony S. K. Mok Abstract Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance. Mok, T. S. K. Nat. Rev. Clin. Oncol. 8, (2011); published online 23 August 2011; doi: /nrclinonc Introduction Historically, non-small-cell lung cancer (NSCLC) was considered to be a single disease entity because the different histologic subtypes into which it can be classified seemed to share the same cause, clinical characteristics and treatment outcomes. For this reason, the same treatment has been used for all patients with NSCLC for the past few decades, and the median overall survival was persistently less than 12 months. 1,2 Only when NSCLC was recognized to be a collection of diseases that are identifiable by molecular abnormalities could treatment be personalized and improved. The first breakthrough towards personalized treatment took place in 2004 when Lynch et al. 3 and Paez et al. 4 reported the presence of activating mutations in the tyrosine kinase domain of EGFR in patients who had a dramatic response to the EGFR tyrosine kinase inhibitor (TKI), gefitinib. Since then, personalized medicine for lung cancer has become a reality. Personalized medicine is not a novel concept. Since the development of traditional Chinese herbal medicine one of the oldest schools of medical therapies treatment has been based on the personalized approach of diag nosis that takes into account the patient s symptoms and the healer s observations. 5,6 The modern approach to personalized cancer medicine is founded on the identification of molecular abnormalities that could account for the patient s disease and, ideally, the identification of a single molecular event that is highly specific to malignant cells. However, hundreds of genomic abnormalities occur in a cancer cell and not all of them are suitable targets for personalized therapy. 7 This is underscored by the fact that the number of successful clinical trials of molecular-targeted therapies for lung cancer is far less than the number of unsuccessful trials. 8 To improve the chances of success in Competing interests T. S. K. Mok declares associations with the following companies: AstraZeneca, Boehringer Ingelheim, Merck Serono, Pfizer and Roche. See the article online for full details of the relationships. the development of personalized medicine for lung cancer we need to know the target, the biomarker, the therapeutic end point, and the mechanisms of resistance. This Review discusses the development and use of drugs targeting activating mutations in EGFR and the oncogenic fusion gene EML4 ALK as outstanding examples of how personalized medicine is a reality for patients with NSCLC. Know the target Multiple mutations occur in NSCLC, and the spectrum of mutations is very different between smokers and nonsmokers, and between squamous-cell carcinoma (SCC) and adenocarcinoma. 7,9 A candidate target for personalized therapy should be specific to the cancer cell and should drive cell proliferation in such a way that inhibit ion of the mutated protein would result in cessation of cancer growth. This information should, ideally, be established using preclinical studies that demonstrate differential growth rates in tumor cells with and without the mutation in the target protein. Clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutat ion is established in a specific population. Lastly, and most importantly, clinical studies of a specific molecular-target ed inhibitor must show a high tumor response rate in patients with the target mutation, a phenomenon that would not be expected in patients without the target mutation. Activating mutations in EGFR are the best-known target in lung cancer. However, when gefitinib was first introduced as a drug targeting EGFR, tumor response rates in unselected patients were persistently below 20%, which was inferior to standard first-line chemotherapy. 10 Preclinical studies testing EGFR TKIs were only performed retrospectively after the discovery of activating mutations in EGFR in Cell growth of lung cancer cell lines transfected with mutant EGFR was inhibited by treatment with EGFR TKIs at much lower concentration than cell lines expressing wild-type EFGR. 11 Multiple Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China. tony@clo.cuhk.edu.hk NATURE REVIEWS CLINICAL ONCOLOGY VOLUME 8 NOVEMBER

2 Key points Personalized medicine should be based on a molecular target that drives cancer cell proliferation, the inhibition of which would cease tumor growth Predictive biomarkers are crucial to identify patients with molecular targets, who are likely to respond better to targeted therapies than to standard therapy Progression-free survival could be an appropriate primary end point in randomized comparative studies with considerable crossover, as overall survival of the two groups would be similar It is likely that patients who benefit from molecular-targeted therapy will eventually become resistant to the drug; understanding the mechanisms of resistance is essential to prevent or defer this process Table 1 Tumor response rate to EGFR TKIs in patients with EGFR mutations Study n Patients with mutations in EGFR (n) EGFR TKI RR (%) Inoue et al. (2009) Gefitinib Rosell et al. (2009) 13 2, Erlotinib Tamura et al. (2008) Gefitinib 75 NA Sutani et al. (2006) Gefitinib TTP (months) Sequist et al. (2007) Gefitinib Abbreviations: NA, not available; RR, response rate; TKI, tyrosine kinase inhibitor; TTP, time to progression. single-arm clinical studies were then carried out, from which we learnt that the tumor response rates to EGFR TKIs in patients with EGFR-mutant tumors ranged from 55% to 78% (Table 1). 10,12 15 The incidence of EGFR mutations in different populations of patients with NSCLC was first assessed by Shigematsu et al. 16 The researchers screened 671 tumor samples and found the incidence of EGFR mutations to be higher in Japanese (26%) and Taiwanese (36%) patients than in American (10%) and Australian patients (12%). 16 In addition, multiple population-based studies were conducted and the data from these studies were summarized in the Review article by Yatabe and Mitsudomi. 17 Among the different studies assessed in the Review, a total of 2,880 patients with lung cancer were included, and the investi gators reported on the incidence of EGFR mutations in Asian versus non-asian patients (32% versus 7%); women versus men (38% versus 10%); never-smokers versus smokers (47% versus 7%); and adenocarcinoma versus non-adenocarcinoma (30% versus 2%). 17 The high response rates to treatment with EGFR TKIs in patients with EGFR-mutant tumors (Table 1) confirmed that the correct target had been identified. 18 However, the drugs still had to be compared against chemotherapy in randomized phase III studies before TKIs were accepted as a standard therapy. The Iressa TM Pan-Asia Study (IPASS) was the first comparative study to confirm that gefitinib is superior to stand ard chemotherapy. 19 Patients with Asian ancestry and adenocarcinoma NSCLC who were light or never-smokers were randomly assigned to receive either gefitinib (250 mg daily) alone or paclitaxel (200 mg/m 2 ) plus carboplatin (5 times AUC). From a total of 1,217 patients, 437 tumor samples were tested for mutations in EGFR and 261 of them (59.7%) were positive. Response rates in patients with mutation-positive tumors were 71.2% and 47.3% in the gefitinib and chemo therapy arms, respectively. Gefitinib significantly improved progression-free survival (PFS) in patients with EGFR-mutant tumors (hazard ratio [HR] = 0.48, P <0.0001), although the drug was associated with adverse outcomes in patients without mutations in EGFR (HR = 2.85, P <0.001). 19 A similar study, FIRST-SIGNAL (FIRST-line Single agent Iressa TM versus Gemcitabine and cisplatin trial in Never-smokers with Adenocarcinoma of the Lung) selected patients by clinical parameters never-smokers and positive for adenocarcinoma and used overall survival as the primary end point. Results were presented at the World Conference in Lung Cancer in 2009 but to date they are only available in abstract form. 20 There was no significant difference in overall survival, but in the small subset of patients (n = 42 out of 96 patients tested) who harbored EGFRactivating mutations, PFS was higher in the gefitinib arm (8.4 months versus 6.7 months, P = 0.08). By contrast, in patients without EGFR-mutant tumors (n = 54) PFS was higher in the chemotherapy arm (2.1 months versus 6.4 months, P = 0.07). These two studies confirmed that patient selection should be based on EGFR-mutation status and not on clinical parameters. The importance of biomarker selection is further supported by four other randomized studies that selected patients with EGFR mutations, who were randomized to receive either EGFR TKIs or chemotherapy (Table 2) The consistently higher response rates and longer PFS have confirmed EGFR TKIs to be a standard therapy for patients with activating mutations in EGFR. Development of inhibitors of the EML4 ALK fusion gene product took a different path. It was previously established that chromosomal translocation of the ALK gene that fuses with nucleophosmin (NPM) results in the expression of an oncogene that drives tumor growth in lymphoma. 25 Soda et al. 26 reported a similar type of translocation in NSCLC that resulted in aberrant fusion of ALK with EML4 and encoded a cytoplasmic chimeric protein with kinase activity. 26 In an in vivo study, the researchers showed that nude mice injected subcutaneously with 3T3 fibroblasts transformed with either the EML4 ALK or NPM ALK fusion gene had substantial tumor growth, whereas tumor growth was not observed with transfection of the ALK or EML4 genes alone. 26 This finding suggested that the EML4 ALK fusion gene was a driver gene of tumorigenesis. However, this is a relatively rare genomic abnormality, and only five of every 75 Japanese patients (6.7%) who were tested harbored the fusion gene. 26 Following this report, the incidence rates in studies in different countries were shown to range from 1.6% to 11.6% The major clinical characteristics of patients with the EML4 ALK fusion gene are similar to those of patients with EGFR mutations, namely nonsmoker and adenocarcinoma. Almost all patients with the EML4 ALK fusion gene do not have mutations in EGFR. 30 The incidence of EML4 ALK fusion seems to be higher in the Chinese population, 27 but this has not been validated and the testing methods are different to other comparable studies. Kwak et al. 31 reported the 662 NOVEMBER 2011 VOLUME 8

3 Table 2 Treatment outcome in patients with EGFR mutations after treatment with a EGFR TKI or chemotherapy Study n Treatment Tumor response rate* (%) Median PFS* (months) IPASS Gefitinib versus paclitaxel + carboplatin 71.2 versus versus 6.4 FIRST-SIGNAL Gefitinib versus gemcitabine + cisplatin 84.6 versus versus 6.7 WJTOG Gefitinib versus docetaxel + cisplatin 62.1 versus versus 6.3 NEJSG Gefitinib versus paclitaxel + carboplatin 73.7 versus versus 5.4 OPTIMAL Erlotinib versus gemcitabine + carboplatin 83.0 versus versus 4.6 EURTAC Erlotinib versus platinum-based doublets 54.5 versus versus 5.2 *EGFR TKI versus chemotherapy. Abbreviations: PFS, progression-free survival; TKI, tyrosine kinase inhibitor. first phase II study of crizotinib, an ALK inhibitor, in patients with the EML4 ALK fusion gene. After screening approximately 1,500 patients for ALK rearrangements, the researchers found 82 ALK-positive patients who were eligible for the study, 96% of whom had adenocarcinoma and 76% of whom were non-smokers and also had adenocarcinoma. The tumor response rate was 57%, and 33% of patients achieved stable disease; PFS was approximately 9.2 months. 31 Similar to EGFR mutations, EML4 ALK has been established as an important molecular target for the management of lung cancer. Two randomized studies comparing crizotinib with standard chemotherapy are ongoing. 32,33 Know the biomarker Targeted therapy implies the use of a specific drug in a selected patient population that expresses the target; thus, the therapy is unlikely to be clinically applicable unless a validated biomarker that identifies the right patients is available (Box 1). 34 Gefitinib was originally developed to target overexpression of EGFR; therefore, high EGFR protein expression levels was initially thought to be a potential predictive biomarker. Only when mutations in EGFR were identified, were both EGFR mutations and EGFR gene-copy number (measured by fluorescence in situ hybridization [FISH]) used as biomarkers in multiple clinical trials. The ISEL 35 and BR studies compared gefitinib and erlotinib, respectively, with placebo in patients who had failed to respond to one or more chemotherapy regimens. Data on the predictive value of EGFR protein expression and EGFR gene-copy number were not consistent. Both biomarkers seemed to be marginally predictive in the ISEL study (interaction test P = and 0.045, respectively) but the two biomarkers were not predictive in the BR 21 study (interaction test P = 0.33 and 0.12, respectively). However, the number of patients who harbored an EGFR mutation was too small (26 and 15 patients for ISEL and BR 21, respectively) for meaningful analysis in these studies; thus, the negative interaction test result should not exclude EGFR mutations as a biomarker. The INTEREST study compared gefitinib with docetaxel as second-line and third-line therapy, and none of the three biomarkers (EGFR protein expression, EGFR gene-copy number, EGFR mutations) were predictive of survival. 37 As before, the small number of patients with EGFR mutations (44 patients) may explain this observation. Conversely, in the IPASS study, EGFR mutations were a robust predictive biomarker for both objective tumor response to gefinitib and PFS (P <0.001), but not for overall survival (P = 0.99). 38 EGFR gene-copy number seemed to be predictive of PFS in patients with high EGFR copy number (HR = 0.66; 95% CI ; P = 0.005). However, there was no signifi cant difference between gefitinib and chemotherapy in patients with low EGFR gene-copy number (HR = 1.24; 95% CI ; P = 0.237). The predictive power of high EGFR gene-copy number can be explained by the concurrent presence of EGFR mutations (78% of all patients with high EGFR copy number) compared with patients with low EGFR gene-copy number, only 33% of whom carried mutations in EGFR. 38 Gefitinib was associated with longer PFS in patients with both high gene-copy number and mutat ions in EGFR (HR = 0.48; 95% CI ); by contrast, chemo therapy was superior to gefitinib in patients with high gene-copy number without mutations in EGFR (HR = 3.85; 95% CI ). 38 Therefore, EGFR mutations should be the predictive biomarker of choice for first-line EGFR TKIs in patients with advanced stage NSCLC. The prognostic or predictive value of EGFR mutations in early-stage NSCLC is less-well defined. Patients with resectable lung cancer who harbor EGFR mutations may have a better survival outcome than patients without EGFR mutations. 39 In a retrospective study of 397 Japanese patients with adenocarcinoma after surgical resection, 197 patients (49%) were found to have EGFR mutations and their overall survival was longer than patients without EGFR mutations (P = ). 39 However, multivariate analysis only confirmed smoking status and not mutations in EGFR to be an independent prognostic factor. Predictive value of EGFR mutations in early-stage disease is also controversial. The BR 19 randomized phase III study compared adjuvant gefitinib with placebo in an unselected patient population with resectable NSCLC. 40 Overall survival of the study population was similar between the two groups (HR = 1.23; P = 0.136). More speci fically, patients with EGFR mutations (n = 76) seemed to have a worse survival outcome with adjuvant gefitinib than with placebo (HR = 1.58; P = 0.18). This surprising outcome may be partly explained by the small sample size and short duration of therapy (the median exposure to gefitinib was 4 months). 40 Alternatively, tumor biology of EGFR mutations in early-stage disease may be different from advanced-stage disease. NATURE REVIEWS CLINICAL ONCOLOGY VOLUME 8 NOVEMBER

4 Box 1 The definition of a biomarker The NIH Biomarkers Definition Working Group defined a biomarker as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. 31 A biomarker is usually a measurable parameter that reflects a normal or physiopathological genomic process. A biomarker can be prognostic, predictive, or both. Being prognostic, the presence of a biomarker is associated with better or worse survival compared with the absence of it. Being predictive, the presence of a biomarker is associated with a greater difference in treatment outcomes when comparing two treatments. The most definitive evidence on the predictive value of a biomarker is its positive interaction test in a randomized comparative study of two active treatments (A and B) such that, in the presence of the biomarker, treatment A attains better outcomes than treatment B, and vice versa in the absence of the biomarker. A genomic biomarker commonly refers to either a single genetic abnormality or a panel of genetic abnormalities. Single abnormalities may be studied at the genetic level using PCR sequencing and fluorescence in situ hybridization, or at the protein level using immunohistochemistry. Multiple genetic abnormalities may be studied using microarrays. A predictive biomarker for targeted therapy should be specific to a single genetic abnormality, otherwise the selection of testing methods and the clinical application of the biomarker could be confusing. Similar to the detection of mutations in EGFR, the EML4 ALK fusion gene can be detected by PCR sequencing, FISH, or immunohistochemical (IHC) staining. However, unlike the development of EGFR mutations as biomarkers for EGFR TKIs, the identification of biomarkers for response to crizotinib is being developed prospectively. Kwak et al. 31 selected all 82 patients for their phase I II study by FISH using an ALK breakpoint probe. A tumor sample was considered ALK positive when 15% or more of the scored cells had either a split 5' and 3' probe or a single 3' signal indicating that the translocation had occurred. Reverse transcription (RT)-PCR and IHC were carried out in a subgroup of 31 patients with available tissue for biomarker study. Only 20 of 29 patients who were ALK-positive as detected by FISH had the EML4 ALK fusion breakpoint confirmed by RT PCR; 19 of 25 ALKpositive patients had ALK expression levels that scored 2+ or 3+ by IHC. Of the four patients who had progressive or stable disease after treatment with crizotinib, two did not have confirmed fusion breakpoint by RT PCR but all four had ALK-positive tumors scoring 2+ by IHC. On the basis of these findings, the investigators decided to use FISH as the standard method of identifying biomarkers in patients enrolled in two subsequent randomized phase III studies. 32,33 The first study enrolled patients who had not responded to first-line chemo therapy and were ALK-positive by FISH, and who were randomly assigned to receive either crizotinib or single-agent chemo therapy (docetaxel or pemetrexed). The second study had a similar design for treatment-naive patients assigned to receive either crizotinib or platinum-based doublet chemo therapy. Both studies are ongoing and may potentially establish the role of crizotinib as firstline, second-line or third-line therapy in ALK-positive patients determined by FISH. 32,33 However, these studies may not confirm the predictive power of FISH as a biomarker; by definition, a positive interaction test is essential for confirmation of the predictive power. As patients without the EML4 ALK fusion gene are not eligible for the study, treatment outcomes to crizotinib in patients not harboring this fusion gene will not be known, either prospectively or retrospectively. Know the end point Overall survival is the most important primary end point for regulatory approval of cytotoxic chemotherapy. This is understandable, given the short treatment duration and limited improvement in survival in either the firstline, second-line or third-line setting in patients with advanced-stage NSCLC. 41,42 The treatment benefit of second-line or third-line chemotherapy is also much less than the benefit of first-line chemotherapy. 43 Development of molecular-targeted therapies poses a new challenge both for investi gators and regulators. Patients with a specific molecular target should respond to targeted therapies independently of the line of therapy. The Spanish Lung Cancer Study Group enrolled 217 patients with EGFR mutations in a single-arm study of erlotinib. 13 Tumor response, PFS and overall survival were similar between patients who received erlotinib as first-line, secondline or third-line therapy. 13 In any randomized study comparing one molecular-targeted therapy with standard chemo therapy, it would be unethi cal not to allow patients in the control arm to cross over to the experimental molecular-targeted drug group upon disease progression. If a significant portion of patients cross over to the study group, overall survival will likely be similar between the two arms. Therefore, PFS is probably the only rational end point for an effective targeted therapy. Figure 1 illustrates the concept of treatment crossover between moleculartargeted therapy and chemotherapy. This phenomenon is exemplified in the IPASS study; 38 despite the dramatic difference in PFS in patients with mutations in EGFR, there was no difference in overall survival between the gefitinib and chemotherapy arm (21.6 months versus 21.9 months; HR = 1.00; 95% CI ; P = 0.990). About 64% of patients who received the combination of paclitaxel and carboplatin as first-line therapy, received EGFR TKIs as post-study therapy. This was also observed in the study by Maemondo et al., 22 in which the median overall survival for the gefinitib and paclitaxel carboplatin arms was 30.5 months and 23.6 months, respectively (P = 0.31). In this study, 94.8% of the patients in the chemotherapy arm crossed over to receive gefitinib and the tumor-response rate in this group was 58.8%. 22 The overall survival outcome of another trial (WJTOG 3405) is immature but preliminary data indicate similar survival outcomes between the gefitinib and chemotherapy arms. 21 Gefitinib has been approved in 75 countries, including in the EU, as first-line therapy for patients with mutations in EGFR. PFS was the primary end point in all four random ized studies that supported the registration The ongoing registration studies of crizotinib in patients with the EML4 ALK fusion gene have also adopted PFS as the primary end point. This paradigm shift will help investigators to design future studies. However, potential shortfalls should be noted. Tumor progression must be rigorously monitored with diagnostic imaging. Unlike cytotoxic chemotherapy, patients may stay on the 664 NOVEMBER 2011 VOLUME 8

5 Diagnosis Chemotherapy Gefitinib DP DP Chemotherapy Gefitinib DP 2 nd or 3 rd line therapy Death months Figure 1 Overall survival in patients with mutations in EGFR receiving TKIs and chemotherapy. Most patients with activating EGFR mutations will benefit from EGFR TKIs irrespective of the line of therapy. Patients who receive a first-line EGFR TKI will have a prolonged PFS and, upon DP*, have a relatively shorter duration of disease controlled by chemotherapy. Patients who receive first-line chemotherapy will have a relatively shorter PFS and, upon DP, have prolonged PFS from second-line EGFR TKI. Patients will have similar overall survival as long as an EGFR TKI is administered during the course of illness. Therefore, PFS is a more valid indicator of treatment effectiveness than overall survival. *DP defined by RECIST criteria. Abbreviations: DP, disease progression; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. targeted drug for many months, and long-term frequent imaging could be a laborious process. Furthermore, most of the past studies did not routinely monitor the central nervous system if the brain was normal at enrollment. As the central nervous system is one of the most common sites of progression for patients receiving TKIs, and many patients may not be symptomatic until significant tumor progression occurs, diagnosis of disease progression could be delayed by this omission. Accurate assessment of PFS should, therefore, include regular imaging of the central nervous system. Know the mechanisms of resistance Molecular-targeted therapies can be effective, but almost all treated tumors will eventually become resistant and progress. Knowing the mechanisms of resistance will help to manage patients at disease progression, and may prevent or defer the process. The main reasons for primary resistance to EGFR TKIs include the absence of EGFR mutations and presence of KRAS mutations, and the two mutations are essentially mutually exclusive. 44 The two major mechanisms of acquired resistance are the EGFR point mutation T790M in exon 20 and overexpression of the components of the hepatocyte growth factor receptor (HGFR, also known as MET) pathway Two independent groups reported the single amino acid change of T790M in EGFR in patients with clinical resistance to gefitinib. 44,45 This substitution alters the conformation of the protein, interfering with the binding of EGFR TKIs and thus restoring ATP binding to the levels of wild-type EGFR. 45 Over 50% of acquired resistance is explained by this mechanism However, whether the T790M mutation pre-exists in a small percentage of cells in treatment-naive tumors or is acquired from exposure to EGFR TKIs remains controversial. Maheswaran et al. 49 reported the presence of the T790M mutation in 28% of tumor samples with no previous exposure to TKIs and, in the IPASS study, of 261 patients with EGFR mutations had the T790M mutation at baseline. The prognostic value of the T790M mutation is also debatable. Using a highly sensitive method, Rosell et al. 50 identified the T790M mutation in 35% of patients enrolled in the Spanish Lung Cancer Study Group trial. Patients with this mutation had a worse PFS when treated with erlotinib than patients without the mutation. However, patients who were found to have the T790M mutation at the time of progression seemed to have slower progressing disease. In a study of 93 patients with a tumor re-biopsy taken at the time of resistance to EGFR TKIs, 58 patients (62%) were found to have the T790M mutation. 51 Median postprogression survival for patients with the T790M mutation was 19 months, which is significantly longer than the median overall survival of 12 months in patients without the T790M mutation (P = 0.036). These data are crucial to future investigation of second-generation irreversible TKIs such as afatinib and PF (Pfizer, New York, USA). Both of these drugs have been shown to inhibit growth in cell lines that harbor the T790M mutation. 52 A phase III study comparing afatinib with placebo in patients with pulmonary adenocarcinoma and previous exposure to an EGFR TKI (LUX Lung 1 study) reported tumor response rates of 13.3% versus 0.5% and PFS of 3.3 months versus 1.1 month (P <0.001), but the study failed to report a significant difference in overall survival. 53 The study considered disease progression after 12 weeks or more of treatment with TKIs erlotinib and gefitinib as the key criterion for EGFR TKI resistance. Tumor re-biopsy was not required and status of exon 20 T790M was unknown at enrollment. Confirming the encouraging preclinical data would require a sufficient proportion of the enrolled patients to present with T790M-related TKI resistance. On the basis of the results from the BR 21 study, an estimated overall survival of the placebo arm of 4.7 months and an HR of 0.70 were expected for the LUX Lung 1 study. However, the median overall survival of the placebo arm in the LUX Lung 1 study was months and, for this reason, there remains the possibility that the study could be statistically underpowered a larger sample size is needed to detect a 2 month difference from a control group with an overall survival of months, than from a control group with an overall survival of 4.7 months. Over 60% of patients in the placebo arm were non-smokers and their median exposure to previous EGFR TKIs was about 9.7 months. In other words, a significant portion of patients in the placebo group carried activating EGFR mutations, which has in general a better prognosis. After a lack of response to placebo, 24% of patients received salvage EGFR TKIs and 43% received standard salvage chemotherapy such as pemetrexed, and this may explain the exceptionally long overall survival. Overexpression of the MET pathway accounts for about 20% of TKI resistance. 47 Tivantinib is a novel TKI targeted against MET. A randomized phase II study in NATURE REVIEWS CLINICAL ONCOLOGY VOLUME 8 NOVEMBER

6 patients with non-squamous cell histology comparing a combination of tivantinib and erlotinib with erlotinib alone reported an improvement in PFS (HR = 0.61, P <0.05) and overall survival (HR = 0.58, P <0.05) favoring the combination arm. 54 Biomarkers, including MET expression by FISH and EGFR mutations by PCR, were not predictive, whereas a small number of patients with KRAS-mutant tumors seemed to survive longer with the combination therapy. A phase III study targeting patients with non-squamous cell histology with no previous exposure to EGFR TKIs is ongoing. Neither this study nor the LUX Lung 1 targeted a biomarker-selected population. Mechanisms of EGFR TKI resistance are heterogeneous and a single drug is unlikely to be effective against the diverse pathologies. Future investigation should involve biopsy of resistant tumors for biomarker analysis, and specific treatment selected according to the mechanisms of resistance if identified. Within a relatively short time of the discovery of the EML4 ALK fusion gene, investigators from Japan have already found two secondary mutations associated with resistance to the ALK inhibitor crizotinib. 55 DNA sequencing and characterization of an EML4 ALK-tumor mutant was performed in a Japanese patient who did not respond to treatment with crizotinib after only 5 months of therapy. 55 The patient harbored point mutations of the residues C1156Y and L1196M in the ALK protein. Lung cancer cell lines transfected with ALK constructs harboring these mutations were much less sensitive to crizotinib, and phosphorylation downstream of ALK was also inhibited. 55 The incidence of these resistant mutations remains unclear. With the ongoing phase III studies of crizotinib in patients with the EML4 ALK fusion gene, hopefully more information on the pattern and frequency of resistance will unfold. Knowing the mechanisms of resistance is not sufficient for future development of personalized medicine for lung cancer. Definition of TKI resistance dictates the duration of therapy, and when treatment is prematurely terminated, patient survival could be indirectly shortened. Jackman et al. 56 proposed four criteria for clinical definition of acquired resistance to EGFR TKIs: clinical exposure to an EGFR TKI, benefit from an EGFR TKI, evidence of disease progression by the RECIST criteria, and lack of exposure to other drugs. 56,57 Biomarkers are not included because our understanding of the biology of acquired resistance is still limited. The problem is the applicability of the RECIST criteria 58 when using moleculartargeted therapies. The criteria are well adopted for clinical investigation of cytotoxic chemotherapy. An increase of 30% in summed maximum diameter or occurrence of new metastatic lesion, are accurate reflections of chemotherapy resistance. 57 However, this principle may not be applicable to molecular-targeted therapies, which are supposed to inhibit cancer cell proliferation that is predominantly driven by a mutated pathway. A new metastatic lesion may only suggest the presence of a resistant clone and not necessarily generalized resistance of other preexisting tumors. In addition to percentage of increase in summed diameter, rate of tumor progression is equally important. Targeted therapies inhibit cancer proliferation continuously. In cases in which the tumor progresses slowly in the presence of a TKI, it is better for the patient to continue with the drug, as cessation of inhibition may lead to rapid tumor growth. 59 The concept of personalized medicine should apply to both treatment selection and treatment cessation. Conclusions Personalized medicine is now a reality for patients with lung cancer. About 10 20% of all patients with lung cancer harbor mutations in EGFR and 3% harbor mutations in EML4 ALK. 10,29 These patients will benefit from EGFR TKI and ALK inhibitors, respectively. Testing for mutations in EGFR for selection of patients for first-line EGFR TKI therapy is standard practice and, in the near future, selection of patients with EML4 ALK for crizotinib treatment will also become a new standard. As most of the patients who harbor mutations in EGFR or EML4 ALK genes are non-smokers, personalized molecular-targeted therapy may not help a large proportion of patients who are smokers. Therefore, future developments will have to identify novel molecular targets that drive cancer growth in smokers. It is likely that these targets are relatively uncommon and drug development will be difficult, but this is a challenge worth undertaking. The successful development of personalized therapy is founded on knowledge of a specific target that drives cancer growth, validation of a clinically applicable biomarker, acceptance of a rational end point, and understanding of the mechanisms of resistance. With each novel target, a standardized biomarker will be developed concurrently. Sequencing technologies will help to identify such biomarkers either in tumor tissue or plasma DNA. Our group used digital PCR to identify mutations in EGFR from plasma and reported high sensitivity and specificity. 60 A mature plasma-based biomarker analysis should make molecular profiling in patients with lung cancer universal, as an adequate tumor sample is not always available. PFS will likely become the standard end point for trials of molecular-targeted therapy in patients with lung cancer. However, the definition of progression may change. In addition to tumor size, progression may be defined according to the molecular profile of the tumor with the emergence of resistant mutations in EGFR, such as T790M or C1156Y. This implies that clinical progression needs to be validated by either re-biopsy or plasmabased biomarker analysis. With such methods, we will be able to learn more about the mechanisms of resistance and provide alternative therapies. Review criteria The relevant articles were identified by the author on the basis of his knowledge of the clinical development of EGFR and EML4 ALK inhibitors. The published data were inclusive of articles from January 2000, and abstracts from major conferences (including the Annual Meeting of ASCO and European Society of Medical Oncology from 2009 to 2011). 666 NOVEMBER 2011 VOLUME 8

7 1. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non small cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26, (2008). 2. Azzoli, C. G. et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non small cell lung cancer. J. Clin. Oncol. 27, (2009). 3. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 350, (2004). 4. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, (2004). 5. Mok, T. S. et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann. Oncol. 18, (2007). 6. Lu, A. P., Jia, H. W., Xiao, C. & Lu, Q. P. Theory of traditional Chinese medicine and therapeutic method of diseases. World J. Gastroenterol. 10, (2004). 7. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455, (2008). 8. Mok, T., Wu, Y. L. & Zhang, L. A small step towards personalized medicine for non-small cell lung cancer. Discov. Med. 8, (2009). 9. Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers a different disease. Nat. Rev. Cancer 7, (2007). 10. Sequist, L. V., Bell, D. W., Lynch, T. J. & Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non small cell lung cancer. J. Clin. Oncol. 25, (2007). 11. Kancha, R. K., von Bubnoff, N., Peschel, C. & Duyster, J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin. Cancer Res. 15, (2009). 12. Inoue, A. et al. First-line gefitinib for patients with advanced non small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 27, (2009). 13. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, (2009). 14. Tamura, K. et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98, (2008). 15. Sutani, A. et al. Gefitinib for non small cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer 95, (2006). 16. Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, (2005). 17. Yatabe, Y. & Mitsudomi, T. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98, (2007). 18. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non small cell lung cancer. J. Clin. Oncol. 21, (2003). 19. Mok, T. S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, (2009). 20. Lee, J. S. et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract]. 13 th World Conference on Lung Cancer PRS.4 (2009). 21. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, (2010). 22. Maemondo, M. et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, (2010). 23. Zhou, C. et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small cell lung cancer (NSCLC) patients with EGFR activating mutations [abstract LBA13]. Ann. Oncol. 21 (Suppl. 8), viii6 (2010). 24. Rosell, R. et al. Erlotinib versus chemotherapy in advanced non small cell lung cancer patients with epidermal growth factor receptor mutations: Interim results of the European Erlotinib vs chemotherapy (EURTAC) phase III randomized trial [abstract]. J. Clin. Oncol. 29 (Suppl.), a7503 (2011). 25. Shiota, M. & Mori, S. The clinicopathological features of anaplastic large cell lymphomas expressing p80npm/alk. Leuk. Lymphoma 23, (1996). 26. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer. Nature 448, (2007). 27. Wong, D. W. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 15, (2009). 28. Perner, S. et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10, (2008). 29. Zhang, X. et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinoma lacking EGFR and KRAS mutation and is correlated with ALK expression. Mol. Cancer 9, 188 (2010). 30. Shaw, A. T. et al. Clinical features and outcome of patients with non small cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, (2009). 31. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N. Engl. J. Med. 363, (2010). 32. US National Library of Medicine. ClinicalTrials.gov [online], NCT (2011). 33. US National Library of Medicine. ClinicalTrials.gov [online], NCT (2011). 34. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, (2001). 35. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, (2005). 36. Shepherd, F. A. et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353, (2005). 37. Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non small cell lung cancer: a randomised phase III trial (INTEREST). Lancet 372, (2008). 38. Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non small cell lung cancer in Asia (IPASS). J. Clin. Oncol. doi: /jco Kosaka, T., Yatabe, Y., Onozato, R., Kuwano, H. & Mitsudomi, T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J. Thorac. Oncol. 4, (2009). 40. Goss, G. D. et al. A phase III prospective, randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non small cell lung cancer (NSCLC): NCIC CTG BR.19 [abstract]. J. Clin. Oncol 28 (Suppl. 18), LBA7005 (2010). 41. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346, (2002). 42. Shepherd, F. A. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, (2000). 43. Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, (2004). 44. Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, (2009). 45. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, (2005). 46. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005). 47. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, (2007). 48. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, (2007). 49. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, (2008). 50. Rosell, R. et al. Pretreatment EGFR T790M mutation and BRCA1 mrna expression in erlotinib-treated advanced non small cell lung cancer patients with EGFR mutation. Clin. Cancer Res. 17, (2011). 51. Oxnard, G. R. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: distinct natural history of patients with tumor harboring the T790M mutation. Clin. Cancer Res. 17, (2011). 52. Belani, C. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest. 28, (2010). NATURE REVIEWS CLINICAL ONCOLOGY VOLUME 8 NOVEMBER

8 53. Miller, V. A. et al. Phase IIb/III trial of afatinib (BIBW 2992) + best supportive care (BSC) vs. placebo + BSC in patients failing 1 2 lines of chemotherapy and erlotinib/gefitinib (LUX Lung 1) [abstract LBA1]. Ann. Oncol. 21 (Suppl. 8), viii1 (2010). 54. Schiller, J. et al. Results from ARQ : a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (Suppl. 18), a7502 (2010). 55. Choi, Y. L. et al. EML4 ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, (2010). 56. Jackman, K. et al. A clinical definition of acquired resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28, (2009). 57. Mok, T. Living with imperfection. J. Clin. Oncol. 28, (2009). 58. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, (2000). 59. Riely, G. et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13, (2007). 60. Yung, T. K. et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PRC in non-small cell lung cancer patients. Clin. Cancer Res. 15, (2009). 668 NOVEMBER 2011 VOLUME 8

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence

EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence 102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi

More information

Molecular Targets in Lung Cancer

Molecular Targets in Lung Cancer Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck

More information

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The

More information

Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung

Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor

More information

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon

More information

Ludger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial

Ludger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel

More information

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome

More information

Changing demographics of smoking and its effects during therapy

Changing demographics of smoking and its effects during therapy Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults

More information

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer. Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor

More information

RESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction

RESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),

More information

Personalized Medicine in Oncology and the Implication for Clinical Development

Personalized Medicine in Oncology and the Implication for Clinical Development THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success

More information

PRACTICE GUIDELINE SERIES

PRACTICE GUIDELINE SERIES ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian

More information

Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC

Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim

More information

SUBJECT: GENOTYPING - EPIDERMAL GROWTH

SUBJECT: GENOTYPING - EPIDERMAL GROWTH MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature

More information

First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?

First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Lihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article

Lihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1

More information

D Ross Camidge, MD, PhD

D Ross Camidge, MD, PhD i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,

More information

Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors

Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One

More information

K-Ras signalling in NSCLC

K-Ras signalling in NSCLC Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation

More information

Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction

Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation

More information

Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients

Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients (2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek

More information

Improving outcomes for NSCLC patients with brain metastases

Improving outcomes for NSCLC patients with brain metastases Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell

More information

Page: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer

Page: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,

More information

Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)

Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic

More information

Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR

Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,

More information

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard

More information

EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS

EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain

More information

Molecular Testing in Lung Cancer

Molecular Testing in Lung Cancer Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans

More information

Personalized Medicine: Lung Biopsy and Tumor

Personalized Medicine: Lung Biopsy and Tumor Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the

More information

Personalized maintenance therapy in advanced non-small cell lung cancer

Personalized maintenance therapy in advanced non-small cell lung cancer China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca

More information

DM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat

DM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials

ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:

More information

EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China

EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang

More information

Sequencing in EGFR-Mutated NSCLC: Does Order Matter?

Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,

More information

Original Article. Abstract

Original Article. Abstract Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line

More information

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department

More information

Molecular Diagnosis of Lung Cancer

Molecular Diagnosis of Lung Cancer Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street

More information

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M

More information

Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory

Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory 2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November

More information

Targeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD

Targeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC

More information

Yan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract

Yan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Introduction ORIGINAL ARTICLE

Introduction ORIGINAL ARTICLE Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective

More information

Personalized Medicine for Advanced NSCLC in East Asia

Personalized Medicine for Advanced NSCLC in East Asia Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,

More information

ALK Fusion Oncogenes in Lung Adenocarcinoma

ALK Fusion Oncogenes in Lung Adenocarcinoma ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of

More information

Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San

Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification

More information

Slide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation

Slide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology

More information

Additional clinical features of this patient include:

Additional clinical features of this patient include: *Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward

More information

State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD

State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung

More information

Recent Advances in Lung Cancer: Updates from ASCO 2017

Recent Advances in Lung Cancer: Updates from ASCO 2017 Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017

More information

Biomarkers in oncology drug development

Biomarkers in oncology drug development Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available

More information

Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC

Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information

AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado

More information

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis 5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory

More information

EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?

EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Test Category: Prognostic and Predictive. Clinical Scenario

Test Category: Prognostic and Predictive. Clinical Scenario Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic

More information

Prognosis of recurrent non small cell lung cancer following complete resection

Prognosis of recurrent non small cell lung cancer following complete resection 1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI

More information

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim

More information

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive

More information

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,

More information

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Original Article Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Yuan-Yuan Lei 1,2, Jin-Ji Yang 2, Wen-Zhao Zhong 2, Hua-Jun Chen

More information

The effi cacy of therapy targeted to a specifi c. Personalized targeted therapy in advanced non small cell lung cancer

The effi cacy of therapy targeted to a specifi c. Personalized targeted therapy in advanced non small cell lung cancer PATRICK C. MA, MD, MS Director, Aerodigestive Oncology Translational Research, Department of Translational Hematology and Oncology Research and Department of Solid Tumor Oncology, Taussig Cancer Institute,

More information

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018 Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung

Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

EGFR TKI sequencing: does order matter?

EGFR TKI sequencing: does order matter? EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer

More information

Introduction. Methods. Patient and study design

Introduction. Methods. Patient and study design Original Article Continuation of gefitinib plus chemotherapy prolongs progressionfree survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations

More information

Delivering Value Through Personalized Medicine: An Industry Perspective

Delivering Value Through Personalized Medicine: An Industry Perspective Delivering Value Through Personalized Medicine: An Industry Perspective Josephine A. Sollano, Dr.PH Head, Global HEOR and Medical Communications Pfizer Oncology, NY, USA josephine.sollano@pfizer.com What

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted

More information

Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line

Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens

More information

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology

More information

Targeted Therapies for Advanced NSCLC

Targeted Therapies for Advanced NSCLC Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting

More information

Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations

Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,

More information

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim

More information

Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer

Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Policy Number: 2.04.45 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

Epidermal growth factor receptor (EGFR) mutations are

Epidermal growth factor receptor (EGFR) mutations are Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,

More information

Medical Policy. MP Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer

Medical Policy. MP Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Medical Policy MP 2.04.45 BCBSA Ref. Policy: 2.04.45 Last Review: 10/30/2017 Effective Date: 10/30/2017 Section: Medicine Related Policies 2.04.115 Molecular Panel Testing of Cancers to Identify Targeted

More information

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians The Harvard community has made this article openly available. Please share how

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY

HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering

More information

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib BioDrugs (2015) 29:167 183 DOI 10.1007/s40259-015-0130-9 REVIEW ARTICLE Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Vera Hirsh 1 Published online: 30 June 2015 The

More information

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17 Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic

More information

Correspondence should be addressed to Kumar Prabhash;

Correspondence should be addressed to Kumar Prabhash; Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating

More information

The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer

The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org

More information

Thoracic and head/neck oncology new developments

Thoracic and head/neck oncology new developments Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening

More information

Cheng-Zhi Zhou*, Yin-Yin Qin*, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ou-Yang, Shi-Yue Li, Rong- Chang Chen

Cheng-Zhi Zhou*, Yin-Yin Qin*, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ou-Yang, Shi-Yue Li, Rong- Chang Chen Original Article Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma Cheng-Zhi Zhou*, Yin-Yin

More information

Slide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years

Slide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable

More information